Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SORBITRATE vs GONITRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sorbitrate (isosorbide dinitrate) is a nitrate that relaxes vascular smooth muscle by converting to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates coronary arteries and peripheral veins (venodilation > arteriodilation), reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.
Prophylaxis of angina pectoris (to reduce frequency and severity of anginal attacks),Chronic management of angina pectoris (as part of long-term therapy),Off-label: Congestive heart failure (adjunctive therapy to reduce preload and afterload),Off-label: Esophageal spasm (symptomatic relief)
Prevention of angina pectoris due to coronary artery disease,Acute relief of angina episodes,Prophylaxis for angina before exertion or stress
Sublingual: 2.5-5 mg as needed for acute angina, up to 10 mg per episode. Oral (sustained-release): 40-80 mg twice daily (immediate-release: 10-20 mg three times daily).
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
Terminal elimination half-life: 5–6 hours. Clinical context: supports dosing every 6–8 hours; requires nitrate-free interval to prevent tolerance.
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Isosorbide dinitrate undergoes extensive first-pass metabolism in the liver via glutathione-dependent organic nitrate reductase (likely mediated by mitochondrial aldehyde dehydrogenase, ALDH2) to active metabolites isosorbide-2-mononitrate and isosorbide-5-mononitrate, with the latter being the major active metabolite. These metabolites are further glucuronidated and excreted renally.
Extensively metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) in vascular smooth muscle; also metabolized by glutathione S-transferases and cytochrome P450 (CYP3A4).
Renal: ~20% unchanged; remainder as metabolites (isosorbide-2-mononitrate, isosorbide-5-mononitrate). Biliary/fecal: negligible.
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
~28% bound to albumin.
60% bound, primarily to plasma albumin
Vd: 1.5–3.5 L/kg. Clinical meaning: extensive tissue distribution, high uptake in vascular smooth muscle.
Approximately 3.3 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle
Sublingual: ~40–60% (bypasses first-pass metabolism). Oral: ~10–20% (extensive first-pass hepatic metabolism).
Sublingual: 40-60%; Oral (immediate-release): <10% due to first-pass hepatic metabolism; Transdermal: 70-90% (drug-in-adhesive); Intravenous: 100%
No dose adjustment required. GFR <10 m L/min: limited data, consider reduced dose.
No specific dose adjustment required for renal impairment. However, use with caution in severe renal dysfunction (Cr Cl <30 m L/min) due to increased risk of hypotension and methemoglobinemia.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% or extend dosing interval.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50% due to decreased clearance. Child-Pugh C: Avoid use or use with extreme caution; consider alternative therapy.
Not recommended for children <18 years due to lack of safety data.
Sublingual: 5-10 mcg/kg/dose, maximum 0.3 mg per dose, may repeat every 5 minutes up to 3 doses. Intravenous: Start at 0.25-0.5 mcg/kg/min, titrate up to 1-5 mcg/kg/min based on response. Not recommended for children <1 year due to limited data.
Start at lower end of dosing range (e.g., sublingual 2.5 mg, oral 10 mg twice daily) due to increased sensitivity and risk of hypotension.
Initiate at lower doses due to increased sensitivity: Sublingual: 0.15-0.3 mg; Transdermal: 0.2 mg/day patch; Intravenous: Start at 5 mcg/min, titrate slowly. Monitor for hypotension and syncope. Avoid sustained-release formulations due to prolonged half-life.
No FDA boxed warning.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension: May cause severe hypotension, especially upon standing (orthostatic hypotension). Correct hypovolemia before use.,Tolerance: Continuous use may lead to development of tolerance; a daily nitrate-free interval (10-12 hours) is recommended to maintain efficacy.,Headache: Common, often dose-limiting; may be severe initially but decreases with continued use.,Worsening angina: Abrupt discontinuation may precipitate angina; taper gradually.,Hypertrophic cardiomyopathy: Use with caution in patients with hypertrophic obstructive cardiomyopathy as vasodilation may worsen outflow obstruction.,Increased intracranial pressure: Use with caution in patients with increased intracranial pressure (e.g., head trauma, cerebral hemorrhage).
Hypotension (especially with volume depletion or diuretic therapy), reflex tachycardia, tolerance (intermittent dosing with nitrate-free interval recommended), abrupt discontinuation may cause angina rebound.
Hypersensitivity to isosorbide dinitrate or any component of the formulation,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe hypotension (systolic BP < 90 mm Hg),Cardiogenic shock (unless used to maintain coronary perfusion pressure with inotropic support),Obstructive cardiomyopathy (relative contraindication),Increased intracranial pressure (relative contraindication)
Concomitant use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil), severe anemia, increased intracranial pressure, hypersensitivity to nitrates, acute myocardial infarction with low filling pressure.
No significant food interactions, but high-fat meals may delay absorption. Avoid excessive alcohol, which can cause additive vasodilation and hypotension.
Avoid alcohol consumption as it may exacerbate nitroglycerin-induced hypotension and vasodilation. No specific food interactions documented; however, patients should maintain adequate hydration. High-fat meals may delay absorption, but sublingual route minimizes this effect. Grapefruit juice has no known interaction.
Isosorbide dinitrate (Sorbitrate) has no well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Due to vasodilatory effects, there is a potential risk of fetal hypoxia, especially during the second and third trimesters. Use only if clearly needed.
FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: risk of fetal bradycardia, hypotension, and reduced uteroplacental perfusion; avoid near term due to risk of maternal hypotension and neonatal bradycardia.
It is not known if isosorbide dinitrate is excreted in human milk. The M/P ratio is unknown. Because many drugs are excreted in milk, caution should be exercised when administered to a nursing woman.
Not recommended during breastfeeding. No data on M/P ratio; minimal excretion into breast milk expected but safety not established. Potential for infant hypotension and bradycardia.
No specific dose adjustments are recommended, but due to increased plasma volume and altered hemodynamics in pregnancy, lower starting doses may be considered, titrating to clinical response. Monitor for hypotension.
No standard dose adjustment required for pregnancy; use lowest effective dose. Increased plasma volume may reduce response; titrate to effect. Avoid in severe preeclampsia or volume depletion.
Sorbitrate (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis, not acute attacks. Sublingual form has faster onset; oral sustained-release provides longer duration. Tolerance develops rapidly with continuous dosing; use a 10-12 hour nitrate-free interval daily. Monitor for hypotension, especially with concurrent PDE-5 inhibitors (e.g., sildenafil) – absolute contraindication due to severe hypotension risk. Headache is common, often transient; advise analgesia. Avoid abrupt discontinuation.
GONITRO (nitroglycerin sublingual powder) is indicated for acute relief of angina pectoris. Administer one packet (0.4 mg or 0.8 mg) at onset of chest pain; may repeat every 5 minutes up to 3 doses. Ensure patient is seated or lying down to avoid hypotension. Do not confuse with oral spray; powder must be placed under tongue. Onset within 1-3 minutes. Common side effect: headache. Contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) within 24-48 hours due to severe hypotension. Monitor for orthostatic hypotension.
Take exactly as prescribed, do not stop abruptly.,For sublingual tablets: place under tongue and let dissolve; do not swallow.,Avoid alcohol as it can worsen dizziness and hypotension.,Prolonged use may lead to tolerance; a daily nitrate-free period is important.,Store tablets in original glass container away from heat and moisture.,Do not use within 24 hours of erectile dysfunction drugs like Viagra, Cialis, or Levitra.,Common side effects: headache, flushing, dizziness; contact doctor if severe or persistent.,If chest pain persists after one sublingual dose, call 911 immediately.
Take one packet at the first sign of chest pain. Empty the entire powder under your tongue and let it dissolve. Do not swallow or rinse with water.,If pain persists after 5 minutes, take a second packet. If still no relief after 5 more minutes, take a third and call 911.,Sit or lie down when taking this medication to prevent dizziness or fainting.,Avoid alcohol; it may worsen side effects like low blood pressure.,Do not use Viagra, Cialis, Levitra, or other erectile dysfunction drugs while on this medicine—serious drop in blood pressure can occur.,Headaches are common; do not stop taking the medication. Over-the-counter pain relievers may help.,Store packets at room temperature away from moisture and heat. Do not open until ready to use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SORBITRATE vs GONITRO, answered by our medical review team.
SORBITRATE is a Nitrate vasodilator that works by Sorbitrate (isosorbide dinitrate) is a nitrate that relaxes vascular smooth muscle by converting to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates coronary arteries and peripheral veins (venodilation > arteriodilation), reducing preload and afterload, thereby decreasing myocardial oxygen demand.. GONITRO is a Nitrate Vasodilator that works by Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SORBITRATE and GONITRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SORBITRATE is: Sublingual: 2.5-5 mg as needed for acute angina, up to 10 mg per episode. Oral (sustained-release): 40-80 mg twice daily (immediate-release: 10-20 mg three times daily).. The standard adult dose of GONITRO is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SORBITRATE and GONITRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SORBITRATE is classified as Category C. Isosorbide dinitrate (Sorbitrate) has no well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Due to vasodilatory effects, there is a poten. GONITRO is classified as Category C. FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.